Harmony Biosciences Holdings, Inc. (HRMY)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Harmony Biosciences Holdings, Inc. reported revenue of $868.45M, up 21.5% from the prior year. The company was profitable, with a net margin of 18.3% and a gross margin of 77.2%. It held $1.27B in total assets against $401.41M in total liabilities.
Key ratios (FY2025)
77.2%
Gross margin
24.0%
Operating margin
18.3%
Net margin
18.2%
Return on equity
+21.5%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $868.45M | $714.73M | $582.02M | $437.86M | $305.44M | $159.74M | $6.00M | — |
| Cost of Revenue | $198.34M | $156.81M | $121.24M | $83.48M | $55.52M | $27.74M | $1.58M | — |
| Gross Profit | $670.11M | $557.92M | $460.79M | $354.37M | $249.92M | $132.00M | $4.42M | — |
| Operating Income | $208.47M | $190.83M | $192.03M | $120.19M | $87.53M | $16.99M | -$145.90M | — |
| Net Income | $158.69M | $145.49M | $128.85M | $181.47M | $34.60M | -$36.94M | -$151.98M | — |
| EPS (Diluted) | $2.71 | $2.51 | $2.13 | $2.97 | $0.58 | $-2.48 | $-24.07 | — |
| Total Assets | $1.27B | $999.20M | $811.45M | $673.87M | $433.44M | $427.07M | $106.70M | — |
| Total Liabilities | $401.41M | $340.05M | $344.46M | $271.03M | $246.94M | $329.89M | $118.29M | — |
| Shareholders' Equity | $870.22M | $659.15M | $466.99M | $402.84M | $186.51M | $97.18M | -$422.86M | -$242.67M |
| Cash & Equivalents | $752.50M | $453.00M | $311.66M | $243.78M | $234.31M | $228.63M | $24.46M | — |
| Operating Cash Flow | $348.20M | $219.82M | $219.39M | $144.47M | $98.56M | -$2.98M | -$75.44M | — |
| Capital Expenditures | $310.0K | $1.15M | $312.0K | $172.0K | $298.0K | $2.0K | $149.0K | — |
| Shares Outstanding | 57.73M | 57.14M | 56.77M | 59.62M | 58.83M | 56.89M | 7.79M | — |